---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-015453"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:10:08.333350+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Monopar Q1 net loss $1.6M; pivots to radiopharma pipeline, winding down other programs

## Summary
- Net loss $1.6M ($0.10/shr) vs $2.4M ($0.19/shr) in Q1 2023.
- Cash and short-term investments $8.8M as of Mar 31, 2024, sufficient through June 2025.
- Company winding down non-radiopharma programs (camsirubicin, MNPR-202) to focus on MNPR-101 radiopharma.
- First-in-human Phase 1 trial of MNPR-101-Zr initiated; targeting MNPR-101-RIT Phase 1 launch by Q4 2024/Q1 2025.
- Additional funding will be needed within the next 12 months to support operations beyond current runway.

## SEC filing metadata
- accession: 0001437749-24-015453
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924015453/0001437749-24-015453-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924015453/mnpr20240502_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-015453
- JSON: https://secwatch.observer/filing/0001437749-24-015453.json
- Plain text: https://secwatch.observer/filing/0001437749-24-015453.txt

## Key facts
- Earnings Releases
  Monopar Therapeutics reported first quarter ended March 31, 2024 results: net income $1.6 million, EPS $0.10 per share.
  - Period: first quarter ended March 31, 2024
  - Net income: $1.6 million
  - EPS: $0.10 per share
  - Result: reported results
  source text: Net loss for the first quarter of 2024 was $1.6 million or $0.10 per share compared to net loss of $2.4 million or $0.19 per share for the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000143774924015453/0001437749-24-015453-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.